Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase
inhibitor is effective in the treatment of epithelial ovarian cancer, primary peritoneal
serous cancer, or fallopian tube cancer for patients who have failed first line
platinum-based therapy and have a persistent rising CA-125.